Zydus Cadila Gets FDA Nod for Depression Drug

Oct 12, 2017

Zydus Cadila has received the final approval from the U.S. FDA to market Desvenlafaxine extended-release tablets, 50 mg and 100 mg. The drug is used to treat major depression and will be manufactured at the group’s formulations manufacturing facility at Moraiya, Ahmedabad.

The company says it now has more than 160 approvals and has filed more than 300 ANDAs since the beginning of the filing process in FY 2003-04.

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments